Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PTTG1
REST API REST API
Homo sapiens
PTTG1 is differentially expressed in 322 experiments: 126 organism parts: bone marrow, testis, ... (124 more);, 246 disease states: normal, colon carcinoma, ... (244 more);, 130 cell types 353 cell lines 36 compound treatments and 74 other conditions.
Synonyms securin, EAP1, PTTG, HPTTG, TUTR1
Orthologs si:dkey-192o1.2 (Danio rerio)   ENSGALG00000001506 (Gallus gallus)   Pttg1 (Mus musculus)   PTTG1_BOVIN (Bos taurus)   si:dkey-192o1.2 (Danio rerio)   PTTG1_RAT (Rattus norvegicus)   ENSBTAG00000046696 (Bos taurus)   ENSBTAG00000047322 (Bos taurus)   XM_536445.2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, cell division, protein binding, DNA repair, regulation of transcription, DNA-dependent, cytoplasm, mitotic cell cycle, SH3 domain binding, chromosome segregation, spermatogenesis, transcription from RNA polymerase II promoter, anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process, nucleus, mitosis, cysteine-type endopeptidase inhibitor activity, chromosome organization, DNA metabolic process, sequence-specific DNA binding transcription factor activity
InterPro Term Securin_separation_inhibitor
UniProt Accession Q2VPE7, O95997, Q9NZH5, C4TNW4, Q6IAL9, E5RJR4
Search EB-eye ENSG00000164611
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (34 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (35 experiments)

Factor Value U/D Experiments
HL-60
2
E-MTAB-37, E-GEOD-24147
MCF7
2
E-GEOD-5258, E-MTAB-37
T84
2
E-GEOD-1474, E-MTAB-37
BT474
1
2
E-MEXP-440, E-MTAB-62, E-MTAB-37
MDA-MB-435
1
E-MTAB-62
NCIH1436
1
E-MTAB-37
347 more value(s).


Cell type

studied in E-GEOD-21668, E-MEXP-750, E-GEOD-20677, E-TABM-34, E-GEOD-2822, ... (58 experiments)

Factor Value U/D Experiments
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
CD4+ T cell
2
3
E-GEOD-16190, E-AFMX-5, E-MTAB-25, E-MTAB-24, E-TABM-145 ... (5 experiments)
CD8+ T cell
1
2
E-AFMX-5, E-MTAB-25, E-TABM-145
stromal cell
1
2
E-GEOD-1460, E-MEXP-2034, E-GEOD-10797
dendritic cell-derived osteoclast
1
E-MEXP-2019
dendritic cell
1
E-GEOD-360
124 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-TABM-15, E-GEOD-16363, ... (75 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-62, E-MTAB-57, E-GEOD-3726, E-MTAB-37
control
4
E-GEOD-21912, E-GEOD-16363, E-GEOD-3185, E-GEOD-16728
lung adenocarcinoma
4
E-MTAB-37, E-GEOD-2514, E-MTAB-62, E-MEXP-231
benign prostatic hyperplasia
2
E-MEXP-1243, E-MEXP-2034
acute lymphoblastic leukemia
2
E-GEOD-96, E-MTAB-62
Burkitt's lymphoma
2
E-GEOD-96, E-MTAB-37
240 more value(s).


Compound treatment

studied in E-GEOD-571, E-MEXP-2449, E-GEOD-6907, E-TABM-782, E-GEOD-5824, ... (20 experiments)

Factor Value U/D Experiments
glucose
1
E-MEXP-941
control - keratinocyte growth factor
1
E-GEOD-7216
Cxcl12
1
E-GEOD-7307
phenol
1
E-GEOD-6907
HMB-PP (phosphoantigen)
1
E-MEXP-1601
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
30 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-4619, ... (10 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, ... (11 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-4025, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-MEXP-421, E-TABM-321, E-GEOD-18005, E-TABM-601, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-GEOD-10315, E-TABM-440, E-GEOD-837, ... (15 experiments)

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-3606, ... (33 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, ... (10 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-GEOD-1676, E-GEOD-3697, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-TABM-43, E-GEOD-1561, ... (8 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.503 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM